Pfizer (NY:PFE)

28.41 -0.11 (-0.37%)

Delayed Quote Updated: 11:02 AM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 24, 2026

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.

Via Benzinga

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal...

Via MarketMinute

Pfizer Stock Is Doing Something It Hasn't Done Since 2022 ↗

March 23, 2026

Up until recently, the stock has been a chronic underperformer.

Via The Motley Fool

Topics Economy Intellectual Property

Pfizer Inc. (NYSE:PFE) Shows Strong Technical Setup for Potential Breakout ↗

March 20, 2026

Via Chartmill

5 High-Yield Stocks to Shield Your Portfolio From the Storm ↗

March 23, 2026

Via MarketBeat

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive ↗

March 23, 2026

Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficacy as Pfizer backs regulatory submissions.

Via Benzinga

Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 23, 2026

Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 results for Lyme disease vaccine. Other stocks also down.

Via Benzinga

Topics Stocks

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

March 23, 2026

From Pfizer Inc.

Via Business Wire

Have $500? 2 Healthcare Stocks Long-Term Investors Should Buy Right Now ↗

March 23, 2026

You can get in on these market giants for bargain prices today.

Via The Motley Fool

Topics Intellectual Property

March 23, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Topics Supply Chain

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

March 20, 2026

From Pfizer Inc.

Via Business Wire

My Top 3 Drug Stocks for March 2026 ↗

March 20, 2026

These companies have impressive track records of navigating the biggest challenges in their industry.

Via The Motley Fool

Topics Intellectual Property

Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗

March 19, 2026

They aren't just "pandemic stocks."

Via The Motley Fool

Topics Intellectual Property

Which S&P500 stocks are the most active on Thursday? ↗

March 19, 2026

Via Chartmill

Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore

March 19, 2026

On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their...

Via Barchart.com

Topics Economy Stocks

Is It Too Late to Buy Eli Lilly? ↗

March 19, 2026

Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.

Via The Motley Fool

Topics Intellectual Property

Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.

March 19, 2026

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.

Via Barchart.com

Topics Earnings

Pfizer Combo Therapy Scores Major Win In Prostate Cancer Trial ↗

March 19, 2026

Pfizer (PFE) shares rise as Talzenna/Xtandi combo hits primary goal in Phase 3 prostate cancer trial. See the full TALAPRO-3 results.

Via Benzinga

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

March 19, 2026

From Pfizer Inc.

Via Business Wire

Looking for the most active stocks in the S&P500 index on Wednesday? ↗

March 18, 2026

Via Chartmill

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

The Best Healthcare Stocks to Buy With $50 Right Now ↗

March 18, 2026

Even on a budget, you can get quality stocks.

Via The Motley Fool

Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Zoetis (NYSE:ZTS)

March 17, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. Looking ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Tuesday's session: most active stock in the S&P500 index ↗

March 17, 2026

Via Chartmill

The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump

March 17, 2026

As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,...

Via MarketMinute

Topics Earnings Economy Initial Public Offering

Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients ↗

March 17, 2026

Pfizer trial results for a new breast cancer treatment showed improved progression-free survival and a manageable safety profile.

Via Benzinga

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

March 17, 2026

From Pfizer Inc.

Via Business Wire

Should You Avoid Pfizer? Here's the Key Risk to Watch ↗

March 17, 2026

Pfizer has reached a turning point.

Via The Motley Fool

Topics Intellectual Property

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

March 17, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper...

Via MarketMinute

Topics Artificial Intelligence Initial Public Offering Stocks

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.